Effects of Elaeagnus angustifolia L. on lipid profile in menopause women

Effects of Elaeagnus angustifolia L. on the lipid profiles in menopause women

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017073132795N3

Enrollment

Registered

2017-10-11

Start date

2017-08-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause. Menopausal and perimenopausal disorder, unspecified

Interventions

Intervention 1: Intervention group: Elaeagnus angustifolia L powder, 15 g / day longer 10 weeks. Intervention 2: Control group(placebo):7.5 g isomalt and 7.5 g corn starch longer 10 weeks.

Treatment - Drugs

Placebo

Intervention group: Elaeagnus angustifolia L powder, 15 g / day longer 10 weeks.

Control group(placebo):7.5 g isomalt and 7.5 g corn starch longer 10 weeks.

Eligibility

Sex/Gender

Female

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Postmenopausal women aged 70-40 with a serum lipid level of 200-300 mg / ml and no risk factor for using the drug to lower this lipid level are invited to this study. Major exclusion criteria: The women who suffering from cardiovascular diseases; renal and metabolic disorders such as diabetes; those using psychiatric drugs; smoking tobacco or consuming alcohol or narcotic agents are excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
LDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Triglyceride. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Insulin. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HbA1c. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Blood pressure. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Total Protein. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.	—

Measure

Time frame

LDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Triglyceride. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Insulin. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HbA1c. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Blood pressure. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Total Protein. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.

—

Secondary

Measure	Time frame
Constipation, Abdominal Pain. Timepoint: End of the course after 10 weeks. Method of measurement: Standards of medical diagnostic laboratories.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahzad SHaabani

Damghan University

mahzadsh70@gmail.com+98 11 4308 3625

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026